Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIETTA phase II trial in systemic diffuse large B-cell lymphoma with CNS involvement
NL-OMON45024Phase 2Active, not recruiting
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cytarabine, thiotepa, ifosfamide and 2 more in diffuse large B-cell lymphoma (DLBCL) and secondary central nervous system lymphoma (SCNSL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: 1-year progression-free survival. Started May 2017; status: active, not recruiting.
02
Drugs
rituximabmethotrexatecytarabinethiotepaifosfamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NL-OMON45024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45024.